Rifaximin in Fatty Liver Disease (RiFL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01355575 |
|
Recruitment Status :
Terminated
(Review of primary endpoint data by study Investigators concluded no further patients required.)
First Posted : May 18, 2011
Last Update Posted : October 17, 2012
|
Sponsor:
Imperial College London
Collaborator:
National Health Service, United Kingdom
Information provided by (Responsible Party):
Imperial College London
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | September 2012 |
| Actual Study Completion Date : | September 2012 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
April 14, 2015 |
April 28, 2015 |
| 2 |
November 10, 2016 |
January 6, 2017 |